Kynurenic acid (KYNA) is a neuroprotective metabolite produced from kynurenine via kynurenine aminotransferases (KATs), functioning as an endogenous antagonist at the glycine co-agonist site of the NMDA receptor and as an agonist at GPR35. It represents the protective branch of the kynurenine pathway, directly opposing the neurotoxic effects of quinolinic acid in a metabolic tug-of-war that determines brain vulnerability to excitotoxicity and neuroinflammation.
Imagine a factory assembly line where raw material (Tryptophan) can be sent down two different conveyor belts. One belt (the kynurenic acid pathway) leads to the safety equipment department β producing protective gear that shields workers from dangerous machinery. The other belt (the quinolinic acid pathway) leads to the demolition department β producing explosive materials. The foreman (IDO or TDO enzyme) decides which belt gets the raw material based on stress signals and inflammation alarms. When the factory is under attack (inflammation, stress), more material gets sent to demolition. But when certain friendly contractors (gut microbiome bacteria) are present in the building, they can reroute some material back to the safety department, producing extra protective gear. Kynurenic acid is that protective gear β it literally blocks the "on" switch (the glycine binding site) of the NMDA receptor demolition machinery, preventing it from over-activating and tearing apart the neural infrastructure. When the factory runs low on safety equipment (low KYNA), even minor stressors can trigger catastrophic damage because the demolition machinery runs unchecked.
Kynurenic acid synthesis and action involves multiple steps with specific enzymatic control points:
Synthesis pathway:
Tryptophan β kynurenine (via IDO or TDO) β kynurenic acid (via kynurenine aminotransferases I-IV, predominantly KAT II in brain)
This pathway competes with the neurotoxic branch:
kynurenine β 3-Hydroxykynurenine β quinolinic acid (via activated Microglia)
Transport:
- Crosses blood-brain barrier via large neutral amino acid transporter (LAT1/SLC7A5)
- Competes with phenylalanine, tyrosine, and other aromatic amino acids for transport
- Peripheral production (especially in liver and gut) contributes to brain concentrations
Receptor mechanisms:
-
NMDA receptor antagonism:
- KYNA binds to glycine co-agonist site (GluN1 subunit) on NMDA receptor
- IC50 = 8-15 ΞΌM at glycine site (competitive inhibition)
- Prevents glycine/D-serine from activating the receptor
- Reduces calcium influx β blocks excitotoxicity cascade
- Also weak antagonist at Ξ±7 nicotinic acetylcholine receptor (IC50 = 7 ΞΌM)
-
GPR35 agonism:
- KYNA activates GPR35 (EC50 = 5-40 ΞΌM depending on species)
- GPR35 activation β Gi protein coupling β decreased cAMP
- Reduces NF-kB activation in immune cells
- Anti-inflammatory effects in gut epithelium and immune cells
Regulatory factors:
Increase KYNA production:
Decrease KYNA production (shift toward quinolinic acid):
graph TD
A[Tryptophan] -->|IDO/TDO| B[Kynurenine]
B -->|"KAT I-IV<br/>+Vitamin B6"| C[Kynurenic acid]
B -->|"KMO<br/>activated microglia"| D[3-Hydroxykynurenine]
D --> E["Quinolinic acid<br/>NEUROTOXIC"]
C -->|antagonist| F["NMDA receptor<br/>glycine site"]
C -->|agonist| G[GPR35]
F --> H["β Glutamate excitotoxicity<br/>β Ca2+ influx"]
G --> I["β NF-ΞΊB<br/>β Inflammation"]
J["Inflammatory cytokines<br/>IFN-Ξ³, TNF-Ξ±"] -.blocks.-> C
K["Butyrate<br/>Lactobacillus"] -.promotes.-> C
L[Stress cortisol] -->|activates TDO| B
Kynurenic acid represents a critical leverage point in cPNI because it sits at the intersection of immune activation, metabolic stress, and neurological protection. This makes it clinically relevant across multiple contexts:
Depression and anxiety:
- Patients with depression show cerebrospinal fluid KYNA levels 40-60% lower than controls
- KYNA/quinolinic acid ratio is more predictive than either alone (normal ratio >2.0, depression often <1.0)
- Low KYNA contributes to NMDA receptor hyperactivity β impaired neuroplasticity and hippocampus dysfunction
- Links the selfish immune system model: chronic Low-Grade Inflammation diverts tryptophan away from protective KYNA production
Chronic pain and fibromyalgia:
- KYNA deficiency increases central sensitization via unopposed NMDA receptor activation
- Patients with Fibromyalgia and chronic pain syndromes show reduced KYNA in cerebrospinal fluid
- This explains why stress (which activates TDO and shifts pathway toward quinolinic acid) worsens pain perception
- Intervention: enhance gut microbiome KYNA production via Lactobacillus strains, Butyrate-producing bacteria
Neurodegenerative disease:
- Alzheimer's Disease: KYNA levels inversely correlate with cognitive decline severity
- Low KYNA β increased glutamate excitotoxicity β accelerated neuronal death
- Parkinson's Disease: reduced KYNA in substantia nigra
- Therapeutic window: increasing brain KYNA 2-3 fold is neuroprotective; excessive increase (>5-fold) may impair cognition via excessive NMDA blockade
Gut-brain axis modulation:
- Represents a key mechanism by which gut microbiome protects brain
- Lactobacillus and Bifidobacterium species can increase peripheral KYNA by 30-50%
- This peripherally-produced KYNA crosses BBB and provides neuroprotection
- Clinical application: probiotic selection should consider KYNA-producing capacity in neurological and psychiatric conditions
Evolutionary mismatch perspective:
- Modern chronic inflammation (driven by processed foods, sedentary behavior, chronic stress) chronically shifts the kynurenine pathway toward quinolinic acid
- Ancestral humans with intermittent acute stress would have maintained better KYNA/quinolinic acid balance
- The selfish brain theory applies: under chronic metabolic stress, the immune system "steals" tryptophan for inflammatory purposes, depleting neuroprotection
Intervention implications:
- KYNA competitively inhibits NMDA receptor at glycine binding site with IC50 of 8-15 ΞΌM
- Normal cerebrospinal fluid KYNA concentration: 10-40 nM in humans
- KYNA/quinolinic acid ratio <1.0 strongly associated with depressive symptoms and cognitive dysfunction
- Crosses blood-brain barrier via LAT1 transporter, competing with aromatic amino acids
- Vitamin B6 is essential cofactor for all four KAT enzymes (deficiency reduces KYNA by 40-60%)
- Butyrate at 1-5 mM upregulates KAT-II expression in colonocytes and astrocytes by 2-3 fold
- Peripheral KYNA production can be increased 30-50% by specific Lactobacillus strains
- Microglia activation shifts kynurenine pathway away from KYNA (can reduce by 70%) toward quinolinic acid
- GPR35 activation by KYNA reduces NF-kB activity by 40-60% in gut epithelial cells
- Chronic stress via cortisol-activated TDO reduces brain KYNA levels by 30-45% within 2-4 weeks
- KYNA has dual role: neuroprotective at physiological levels, but excessive elevation (>200 nM CSF) may impair cognition by over-blocking NMDA receptors required for learning
- Half-life of KYNA in brain is approximately 45-60 minutes, requiring continuous production
- kynurenine pathway β KYNA is the protective branch, competing with the neurotoxic quinolinic acid branch for the same substrate
- quinolinic acid β neurotoxic counterpart; KYNA/quinolinic acid ratio determines net neurotoxicity vs neuroprotection
- NMDA receptor β KYNA is endogenous antagonist at the glycine co-agonist binding site, reducing excitotoxicity
- GPR35 β KYNA acts as agonist at this orphan receptor, mediating anti-inflammatory effects in gut and immune cells
- Tryptophan β precursor molecule that feeds the entire kynurenine pathway
- IDO β indoleamine 2,3-dioxygenase that initiates kynurenine pathway, activated by inflammatory cytokines
- TDO β tryptophan 2,3-dioxygenase activated by cortisol during stress, shunting tryptophan away from serotonin toward kynurenine
- Microglia β activated microglia express enzymes that divert kynurenine toward quinolinic acid instead of KYNA
- neuroinflammation β KYNA provides protection through NMDA antagonism and GPR35-mediated anti-inflammatory effects
- glutamate β KYNA reduces glutamate excitotoxicity by blocking NMDA receptor activation
- blood-brain barrier β KYNA crosses via LAT1 large neutral amino acid transporter
- gut microbiome β specific bacterial strains enhance peripheral KYNA production, providing systemic and central neuroprotection
- Butyrate β upregulates KAT enzyme expression, shifting pathway toward KYNA production
- depression β reduced KYNA levels and low KYNA/quinolinic ratio contribute to depressive pathophysiology
- Fibromyalgia β KYNA deficiency increases central sensitization and pain amplification
- neuropathic pain β low KYNA allows unopposed NMDA receptor activation, driving central sensitization
- Vitamin B6 β essential cofactor for all KAT enzymes; deficiency impairs KYNA synthesis
- inflammatory cytokines β IFN-Ξ³, TNF-Ξ±, and IL-6 activate IDO and shift pathway away from KYNA toward quinolinic acid
- chronic inflammation β chronically depletes neuroprotective KYNA production via immune system tryptophan consumption
- TLR4 β activation by LPS reduces KYNA/quinolinic acid ratio by polarizing microglia toward neurotoxic branch
- vagus nerve β vagal stimulation may enhance KYNA production through anti-inflammatory effects and gut microbiome modulation
- cognitive decline β KYNA deficiency associated with accelerated cognitive impairment and reduced neuroprotection
- Alzheimer's Disease β reduced KYNA levels in brain correlate with disease severity and cognitive decline
- cortisol β chronically elevated cortisol activates TDO, reducing available tryptophan for both serotonin and KYNA production
- Lactobacillus β specific species produce KYNA peripherally, providing cross-barrier neuroprotection
- Short-chain fatty acids β particularly butyrate enhances KAT expression and KYNA synthesis
- brain-gut axis β KYNA represents a key molecular mediator of microbiome effects on brain function
- Anxiety β low KYNA contributes to NMDA receptor hyperactivity and anxious symptomatology
- chronic pain syndromes β KYNA deficiency is common mechanism underlying central sensitization across multiple pain conditions
- central sensitization β inadequate KYNA allows excessive NMDA receptor activation, driving pain amplification